BioRestorative Therapies, Inc.
BRTXNasdaq
$0.33
↓ -4.8%Jul 17 close · end-of-day
Price
1Y↓ -79.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.9M
Enterprise Value
$2.3M
P/E
—
P/S
16.6
P/B
2.0
EV/EBITDA
—
PEG
—
FCF Yield
-184.1%
Dividend Yield
—
Revenue (TTM)
$357,870.00
Net Income (TTM)
-$11.1M
Free Cash Flow (TTM)
-$10.9M
Gross Margin
92.1%
Operating Margin
-3975.0%
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
—
Net Cash
$3.6M
Return 1Y
-79.0%
Company profile
The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies in August 2011.
- CEO
- Lance Alstodt
- Sector
- Services
- Industry
- Healthcare
- Employees
- 7
- Headquarters
- New York
- Website
- biorestorative.com
Management & directors
- Alstodt LancePresident, CEO, COB
- Silva FranciscoVP of Research and Development
Roles derived from SEC Form 4 filings.
Earnings
BRTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$23,170.00↓ -7.3%
Diluted EPS-$0.12↓ -81.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $77,000.00 | $46,000.00 | $119,800.00 | $145,800.00 | $401,000.00 | $359,700.00 |
| Gross profit | — | — | — | $145,800.00 | $372,928.00 | $335,856.00 |
| Operating income | -$2.8M | -$26.3M | -$19.0M | -$15.2M | -$11.6M | -$15.6M |
| Net income | -$11.3M | -$44.3M | -$13.2M | -$10.4M | -$9.0M | -$14.2M |
| Diluted EPS | — | — | -$3.65 | -$2.47 | -$1.16 | -$1.58 |
| Operating cash flow | -$2.0M | -$3.3M | -$5.9M | -$6.4M | -$8.2M | -$10.8M |
| Free cash flow | — | -$3.4M | -$6.2M | -$6.6M | -$8.3M | -$10.9M |
| Gross margin | — | — | — | 100.0% | 93.0% | 93.4% |
| Operating margin | -3574.1% | -57191.0% | -15838.1% | -10439.5% | -2881.6% | -4350.1% |
| Net margin | -14639.9% | -96311.5% | -11037.0% | -7145.2% | -2239.2% | -3959.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $89,100.00 | $233,600.00 | $43,300.00 | $25,000.00 | $303,300.00 | $11,800.00 | $19,600.00 | $23,170.00 |
| Gross profit | $82,610.00 | $215,357.00 | $39,961.00 | $22,091.00 | $294,571.00 | $1,230.00 | $17,964.00 | $15,785.00 |
| Operating income | -$2.5M | -$2.3M | -$2.7M | -$4.8M | -$3.3M | -$3.7M | -$3.8M | -$3.4M |
| Net income | -$4.0M | -$1.1M | -$1.6M | -$5.3M | -$2.7M | -$3.0M | -$3.2M | -$2.2M |
| Diluted EPS | -$0.50 | -$0.13 | -$0.20 | -$0.64 | -$0.30 | -$0.33 | -$0.31 | -$0.12 |
| Operating cash flow | -$1.9M | -$1.7M | -$2.3M | -$2.8M | -$2.7M | -$2.9M | -$2.4M | -$3.8M |
| Free cash flow | — | -$1.8M | — | -$2.8M | -$2.7M | -$2.9M | -$2.5M | — |
| Gross margin | 92.7% | 92.2% | 92.3% | 88.4% | 97.1% | 10.4% | 91.7% | 68.1% |
| Operating margin | -2770.8% | -979.0% | -6212.8% | -19230.1% | -1089.8% | -31432.3% | -19516.8% | -14612.6% |
| Net margin | -4521.4% | -467.2% | -3778.6% | -21359.2% | -875.8% | -25748.1% | -16365.5% | -9298.3% |
Company news
May 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-06 | ALSTODT LANCE· President, CEO, COB | Award | 15,625 | $1.60 | $25,000.00 | filing |
| 2025-10-06 | Silva Francisco· VP of Research and Development | Award | 11,719 | $1.60 | $18,750.40 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.